18F-Fluciclovine PET/CT: A Potential Imaging Biomarker for the Evaluation of Multiple Myeloma

Clin Nucl Med. 2022 Sep 1;47(9):e613-e615. doi: 10.1097/RLU.0000000000004271. Epub 2022 May 12.

Abstract

Incidental concomitant second primary malignancy may be detected on PET/CT imaging. We present an 18F-fluciclovine PET/CT of a patient undergoing evaluation of biochemically recurrent prostate cancer with incidental radiotracer uptake within lytic osseous lesions confirmed to be multiple myeloma. We present the 18F-fluciclovine PET/CT images of an 83-year-old man with prostate cancer treated in 2005 who presented with back pain and a CT scan revealing multiple lytic osseous lesions concerning for metastases versus a plasma cell neoplasm. Prostate-specific antigen at the time of evaluation was 0.1 ng/mL.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Bone and Bones / pathology
  • Carboxylic Acids
  • Cyclobutanes*
  • Humans
  • Male
  • Multiple Myeloma* / diagnostic imaging
  • Positron Emission Tomography Computed Tomography / methods
  • Prostatic Neoplasms* / pathology
  • Tomography, X-Ray Computed

Substances

  • Carboxylic Acids
  • Cyclobutanes